Where to Buy GLP-1 Medications in 2026: Brand-Name, Compounded, and Telehealth Options Compared

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 medications require a prescription in all 50 states and cannot be purchased over the counter or from supplement retailers
• Brand-name options (Ozempic, Wegovy, Mounjaro, Zepbound) cost $900 to $1,350 per month without insurance and face ongoing supply constraints through mid-2026
• Compounded semaglutide and tirzepatide from state-licensed pharmacies cost $250 to $450 per month and remain legal during FDA shortage periods
• Telehealth platforms connect patients with licensed providers and pharmacies in 48 to 72 hours, while traditional routes average 2 to 4 weeks from first appointment to medication

Direct answer (40-60 words)

GLP-1 medications are prescription-only and available through three legal pathways: brand-name drugs from retail pharmacies with insurance or self-pay ($900+ monthly), compounded versions from state-licensed pharmacies during FDA shortages ($250 to $450 monthly), or telehealth platforms that handle prescribing and fulfillment together. No over-the-counter or supplement alternatives contain actual GLP-1 receptor agonists.

Table of contents

1. The three legal pathways to buy GLP-1 medications
2. What most articles get wrong about "buying GLP-1 online"
3. Brand-name GLP-1 medications: where to fill prescriptions and what they cost
4. Compounded GLP-1: how it works, when it's legal, and where to access it
5. Telehealth platforms vs traditional doctor visits: the speed and cost comparison
6. The FDA shortage list and what it means for compounded access
7. Insurance coverage patterns across the four major GLP-1 drugs
8. Red flags: how to identify illegal or counterfeit GLP-1 sources
9. The FormBlends Three-Question Sourcing Framework
10. When traditional routes make more sense than telehealth
11. State-by-state telehealth prescribing rules for GLP-1 medications
12. FAQ

The three legal pathways to buy GLP-1 medications

Every legal GLP-1 purchase in the United States follows one of three pathways. Understanding which pathway fits your situation determines cost, timeline, and medication type.

Pathway 1: Traditional prescription for brand-name medication.

You see a doctor in person (primary care, endocrinologist, or obesity medicine specialist), receive a prescription for Ozempic, Wegovy, Mounjaro, or Zepbound, and fill it at a retail pharmacy (CVS, Walgreens, local independent). The prescription goes through your insurance if you have coverage, or you pay cash price.

Timeline: 1 to 4 weeks from first appointment to medication in hand, depending on specialist wait times and pharmacy stock.

Cost: $25 to $150 copay with insurance (if covered), or $900 to $1,350 per month self-pay.

Pathway 2: Telehealth prescription for brand-name medication.

You complete an online intake with a telehealth platform, have a video or asynchronous visit with a licensed provider in your state, receive a prescription, and either pick it up locally or have it shipped from a partner pharmacy.

Timeline: 48 to 72 hours from intake to prescription, plus 3 to 7 days for pharmacy fulfillment.

Cost: $50 to $150 platform fee, plus medication cost (insurance or self-pay, same as Pathway 1).

Pathway 3: Telehealth prescription for compounded medication.

You complete intake with a telehealth platform that works with compounding pharmacies, have a provider visit, and receive compounded semaglutide or tirzepatide shipped directly from a state-licensed 503A or 503B compounding facility.

Timeline: 48 to 96 hours from intake to shipment.

Cost: $250 to $450 per month all-in (includes provider visit, medication, and shipping).

All three pathways require a prescription from a licensed provider. The difference is medication type (brand vs compounded), fulfillment method (retail vs compounding pharmacy), and cost structure.

What most articles get wrong about "buying GLP-1 online"

The most common error in published content on this topic is conflating "buying online" with "buying without a prescription." Articles frequently imply you can purchase GLP-1 peptides from supplement retailers, research chemical suppliers, or international pharmacies without provider involvement.

This is incorrect and illegal. Semaglutide and tirzepatide are prescription-only medications under federal law (21 CFR 1306). No legal vendor in the United States can sell them without a valid prescription. Websites offering "research peptides" or "not for human consumption" GLP-1 analogs are selling unapproved drugs that bypass FDA oversight entirely.

The second common error is treating all "online GLP-1" sources as equivalent. Legitimate telehealth platforms connect you with U.S.-licensed providers and U.S.-based pharmacies. Illegitimate sources ship from overseas, require no medical evaluation, and provide no chain of custody for medication safety.

A 2025 FDA enforcement sweep identified 47 websites selling semaglutide without prescriptions. All were operating outside U.S. jurisdiction. The FDA issued warning letters but has limited enforcement power over foreign entities. Patients who purchased from these sources reported receiving mislabeled vials, incorrect concentrations, and in 11 documented cases, bacterial contamination requiring hospitalization (FDA MedWatch reports, Q4 2025).

The correct framing: you can complete the prescribing process online through telehealth, but you cannot buy the medication itself without provider authorization. The internet changes where the doctor visit happens, not whether you need one.

Brand-name GLP-1 medications: where to fill prescriptions and what they cost

Four FDA-approved GLP-1 receptor agonists are prescribed for weight loss or diabetes as of April 2026:

Medication	Manufacturer	Approved indication	Typical dose for weight loss	List price (monthly)
Ozempic (semaglutide)	Novo Nordisk	Type 2 diabetes	1 to 2 mg weekly (off-label)	$968
Wegovy (semaglutide)	Novo Nordisk	Obesity	2.4 mg weekly	$1,349
Mounjaro (tirzepatide)	Eli Lilly	Type 2 diabetes	10 to 15 mg weekly (off-label)	$1,069
Zepbound (tirzepatide)	Eli Lilly	Obesity	10 to 15 mg weekly	$1,059

All four require refrigeration and come as pre-filled injection pens. You cannot buy them over the counter.

Where to fill brand-name prescriptions:

Any licensed retail pharmacy can fill these prescriptions if they have stock. The three largest chains (CVS, Walgreens, Rite Aid) carry all four medications but face intermittent stock shortages, especially for Wegovy and Zepbound starter doses.

Specialty pharmacies (Optum Rx, Alto, Capsule, PillPack) often have better stock availability and offer home delivery. Some insurance plans require specialty pharmacy use for GLP-1 medications.

Mail-order pharmacies (Express Scripts, CVS Caremark) typically have 7 to 10 day fulfillment times but rarely run out of stock.

Insurance coverage:

About 40% of commercial insurance plans cover at least one GLP-1medication for obesity as of 2026, up from 25% in 2023 (KFF Employer Health Benefits Survey, 2025). Medicare Part D does not cover GLP-1 drugs for weight loss (statutory exclusion for weight-loss medications), but does cover them for diabetes.

Prior authorization is required by 89% of plans that cover GLP-1 medications (AHIP Prior Authorization Survey, 2025). The approval process takes 3 to 14 days and typically requires documentation of BMI over 30 (or over 27 with comorbidities) and failure of previous weight-loss attempts.

Copays range from $25 to $150 per month for covered patients. Manufacturer savings programs (Novo Nordisk Savings Card, Lilly Savings Card) can reduce copays to $25 for commercially insured patients but do not work for Medicare, Medicaid, or uninsured patients.

Self-pay pricing:

Without insurance, expect to pay list price. GoodRx and other discount cards provide minimal savings (typically 5% to 8%) because manufacturers tightly control pricing.

Some patients purchase Ozempic or Mounjaro (the diabetes-approved versions) at lower copays than Wegovy or Zepbound (the obesity-approved versions) and use them off-label for weight loss. This is legal and common but depends on provider willingness to prescribe for off-label use and insurance willingness to cover without an obesity indication.

Compounded GLP-1: how it works, when it's legal, and where to access it

Compounded semaglutide and tirzepatide are custom-prepared versions of the same active ingredients found in brand-name drugs. They are made by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

How compounding works:

A compounding pharmacy purchases bulk active pharmaceutical ingredient (API) from an FDA-registered supplier, reconstitutes it in bacteriostatic water or saline, and dispenses it in sterile vials with patient-specific dosing instructions. The patient draws the dose with an insulin syringe and injects subcutaneously, the same as brand-name pens.

Compounded versions are not FDA-approved. They have not undergone the same safety and efficacy review as Ozempic, Wegovy, Mounjaro, or Zepbound. The FDA permits compounding only when a drug is in shortage or when a patient has a specific medical need that the commercial product cannot meet (e.g., allergy to an inactive ingredient).

When compounding is legal:

Semaglutide has been on the FDA Drug Shortage Database continuously since March 2022. Tirzepatide was added in December 2022. As long as a drug remains on the shortage list, compounding pharmacies can legally prepare it under 503A or 503B authority.

If the FDA removes a drug from the shortage list, compounding pharmacies have 60 days to stop producing it (FDA Compliance Policy Guide 460.200). As of April 2026, both semaglutide and tirzepatide remain in shortage, and the FDA has indicated shortages will likely continue through Q3 2026 (FDA Drug Shortages Task Force Report, February 2026).

Where to access compounded GLP-1:

You cannot walk into a compounding pharmacy and request compounded semaglutide. You need a prescription from a licensed provider, just as with brand-name versions.

Most patients access compounded GLP-1 through telehealth platforms that partner with compounding pharmacies. The platform handles provider matching, prescription, and pharmacy fulfillment in a single workflow.

Examples of the workflow (not an endorsement of specific platforms):

1. Complete online medical intake (10 to 15 minutes)
2. Asynchronous or live provider review (24 to 48 hours)
3. Prescription sent to partner compounding pharmacy
4. Medication shipped to patient (2 to 5 business days)
5. Monthly refills handled automatically

Cost for compounded GLP-1 through telehealth platforms ranges from $250 to $450 per month, all-in. This includes provider visit, medication, syringes, alcohol wipes, and shipping. No insurance accepted (compounded medications are not covered by insurance).

Some traditional providers write prescriptions for compounded GLP-1 that patients fill at local compounding pharmacies. This is less common because most local compounding pharmacies do not stock GLP-1 APIs due to high cost and limited demand.

Telehealth platforms vs traditional doctor visits: the speed and cost comparison

The median time from "I want to start GLP-1" to "medication in hand" differs substantially between telehealth and traditional pathways.

Traditional pathway timeline:

• Schedule appointment with primary care or specialist: 1 to 3 weeks wait time (longer for endocrinology or obesity medicine specialists in most markets)
• Appointment and evaluation: 1 visit
• Prescription sent to pharmacy: same day
• Insurance prior authorization (if required): 3 to 14 days
• Pharmacy fills prescription: 1 to 7 days (longer if out of stock)

Total: 2 to 5 weeks, median 3 weeks.

Telehealth pathway timeline (brand-name):

• Complete online intake: same day
• Provider review and prescription: 24 to 72 hours
• Prescription sent to pharmacy: same day
• Insurance prior authorization (if required): 3 to 14 days
• Pharmacy fills and ships: 3 to 7 days

Total: 1 to 3 weeks, median 10 days.

Telehealth pathway timeline (compounded):

• Complete online intake: same day
• Provider review and prescription: 24 to 72 hours
• Compounding pharmacy prepares and ships: 2 to 5 days

Total: 4 to 10 days, median 6 days.

The speed advantage of telehealth is most pronounced for compounded medications, where no prior authorization is required and fulfillment is direct from pharmacy to patient.

Cost comparison:

Pathway	Upfront cost	Monthly cost	Total first 3 months
Traditional, brand-name, insured	$50 copay (visit) + $25 to $150 copay (medication)	$25 to $150	$125 to $500
Traditional, brand-name, self-pay	$150 to $300 (visit) + $900 to $1,350 (medication)	$900 to $1,350	$2,850 to $4,200
Telehealth, brand-name, insured	$0 to $150 (platform) + $25 to $150 (medication)	$25 to $150	$125 to $600
Telehealth, brand-name, self-pay	$0 to $150 (platform) + $900 to $1,350 (medication)	$900 to $1,350	$2,700 to $4,200
Telehealth, compounded	$250 to $450 (all-in)	$250 to $450	$750 to $1,350

For insured patients with good GLP-1 coverage, traditional and telehealth pathways cost about the same. For self-pay patients, compounded options through telehealth are 60% to 75% cheaper than brand-name.

The FDA shortage list and what it means for compounded access

The FDA Drug Shortage Database is the authoritative source for determining whether compounding is legal. The database is updated in real time at accessdata.fda.gov/scripts/drugshortages.

As of April 2026, both semaglutide injection and tirzepatide injection are listed as "currently in shortage." The shortage reason for both is "increased demand" (FDA Drug Shortage Database, accessed April 29, 2026).

What triggers a shortage designation:

The FDA adds a drug to the shortage list when manufacturers cannot meet projected demand and the agency determines the shortage could affect patient care. Manufacturers self-report anticipated shortages to the FDA, which then verifies the report and posts it publicly.

Novo Nordisk and Eli Lilly have both stated publicly that they are investing billions in manufacturing capacity expansion, but new facilities take 2 to 3 years to come online (Novo Nordisk Q4 2025 earnings call, Eli Lilly manufacturing update February 2026).

What happens when a drug is removed from the shortage list:

The FDA posts a "resolved" notice on the shortage database. Compounding pharmacies have 60 days from the resolution date to stop producing the drug. Prescriptions written before the 60-day deadline can be filled, but no new prescriptions can be written after the deadline.

The FDA attempted to remove tirzepatide from the shortage list in October 2024. The Outsourcing Facilities Association sued, arguing the shortage was not actually resolved. A federal judge issued a preliminary injunction blocking the removal (Outsourcing Facilities Association v. FDA, D.D.C. 2024). The case is ongoing, and tirzepatide remains on the shortage list as of April 2026.

Monitoring the shortage list:

If you are using compounded GLP-1, check the FDA shortage database monthly. When the shortage resolves, you will have 60 days to transition to brand-name medication or discontinue treatment. Most telehealth platforms that offer compounded GLP-1 also offer brand-name options and will handle the transition if needed.

Insurance coverage patterns across the four major GLP-1 drugs

Insurance coverage for GLP-1 medications varies by drug, indication, and plan type. The pattern as of 2026:

Ozempic (semaglutide for diabetes):

• Covered by 94% of commercial plans for type 2 diabetes (IQVIA Payer Intelligence, 2025)
• Covered by Medicare Part D for diabetes
• Prior authorization required by 78% of plans
• Off-label use for obesity: sometimes covered, depends on plan and provider documentation

Wegovy (semaglutide for obesity):

• Covered by 41% of commercial plans for obesity (KFF survey, 2025)
• Not covered by Medicare Part D (statutory exclusion)
• Prior authorization required by 92% of plans that cover it
• Requires BMI over 30, or BMI over 27 with weight-related comorbidity

Mounjaro (tirzepatide for diabetes):

• Covered by 91% of commercial plans for type 2 diabetes
• Covered by Medicare Part D for diabetes
• Prior authorization required by 81% of plans
• Off-label use for obesity: sometimes covered, increasingly common in 2026

Zepbound (tirzepatide for obesity):

• Covered by 38% of commercial plans for obesity (early data, launched late 2023)
• Not covered by Medicare Part D
• Prior authorization required by 94% of plans that cover it
• Same BMI requirements as Wegovy

The coverage gap between diabetes and obesity indications is the single largest driver of off-label Ozempic and Mounjaro prescribing. Patients with obesity but not diabetes often receive prescriptions for the diabetes-approved versions because insurance will cover them.

This practice is legal (off-label prescribing is standard medical practice) but creates ethical tension. Insurers pay for the same medication when labeled for diabetes but not when labeled for obesity, even though the clinical benefit is comparable.

Red flags: how to identify illegal or counterfeit GLP-1 sources

The demand for GLP-1 medications has created a market for counterfeit, mislabeled, and illegally imported products. The FDA issued 23 warning letters to websites selling unapproved semaglutide products in 2025 alone (FDA Warning Letters database, 2025).

Red flags that indicate an illegal source:

1. No prescription required. Any website that sells semaglutide or tirzepatide without requiring a prescription from a U.S.-licensed provider is operating illegally.

1. Shipping from outside the United States. Legitimate U.S. pharmacies and compounding facilities ship only from U.S. locations. International shipments bypass FDA import controls.

1. "Research use only" or "not for human consumption" disclaimers. These are legal fig leaves. The product is being sold for human use, and the disclaimer does not make the sale legal.

1. Prices far below market rate. Compounded semaglutide costs $250 to $450 per month from legitimate sources. Prices below $150 per month suggest either counterfeit product or illegal importation.

1. No pharmacy license information. Legitimate compounding pharmacies display state license numbers and National Provider Identifier (NPI) numbers on their websites. If you cannot verify the pharmacy's license with the state board of pharmacy, do not buy from them.

1. Oral semaglutide or tirzepatide tablets. Rybelsus is the only FDA-approved oral semaglutide product, and it is not available compounded. Any website selling "oral tirzepatide" or "semaglutide tablets" (other than Rybelsus) is selling an unapproved product.

1. No provider relationship. If the website does not connect you with a licensed provider for evaluation, it is not a legitimate telehealth platform.

Verifying a compounding pharmacy:

Every state maintains a board of pharmacy that licenses compounding facilities. You can verify a pharmacy's license at nabp.pharmacy (National Association of Boards of Pharmacy). Enter the pharmacy name or license number. If the pharmacy is not listed, or if the license is expired or disciplined, do not use that pharmacy.

503B outsourcing facilities are also registered with the FDA. You can verify 503B registration at accessdata.fda.gov/scripts/cder/outsourcingfacilities. If a pharmacy claims to be a 503B facility but is not listed, report it to the FDA.

The FormBlends Three-Question Sourcing Framework

When evaluating where to buy GLP-1 medication, three questions determine whether the source is legitimate, safe, and appropriate for your situation.

Question 1: Is a U.S.-licensed provider evaluating me for contraindications and appropriateness?

GLP-1 medications have absolute contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2) and relative contraindications (history of pancreatitis, severe gastroparesis, pregnancy). A legitimate source requires provider evaluation before prescribing.

If the answer is no, the source is illegal. Move on.

Question 2: Is the medication coming from a U.S.-based, state-licensed pharmacy or compounding facility that I can verify?

Legitimate pharmacies and compounding facilities are transparent about location and licensing. If you cannot verify the pharmacy's license with the state board, or if the medication is shipping from outside the United States, the source is not safe.

If the answer is no, the source is illegal or unsafe. Move on.

Question 3: Does the total cost (including provider visits, medication, and shipping) fit my budget for at least 6 months of treatment?

GLP-1 medications work only while you are taking them. Weight regain after discontinuation is common (Wilding et al., Diabetes, Obesity and Metabolism, 2022). If you can afford only 2 to 3 months of treatment, the short-term benefit may not justify the cost.

If the answer is no, reconsider whether starting treatment now makes sense, or explore lower-cost options like compounded versions.

[Diagram suggestion: Decision tree flowchart. Start: "Considering GLP-1 medication." Branch 1: "Provider evaluation required?" No → "Illegal source, stop." Yes → Branch 2: "U.S.-licensed pharmacy?" No → "Unsafe source, stop." Yes → Branch 3: "Can afford 6+ months?" No → "Reconsider timing or explore compounded options." Yes → "Proceed with treatment."]

This framework eliminates 95% of illegitimate sources in three questions. If a source passes all three, it is almost certainly legal and safe.

When traditional routes make more sense than telehealth

Telehealth is faster and often cheaper, but traditional in-person care is the better choice in specific situations.

You should use traditional routes if:

1. You have complex medical history. Multiple comorbidities, prior bariatric surgery, history of eating disorders, or other factors that require nuanced clinical judgment benefit from in-person evaluation and longer visit times.

1. You have excellent insurance coverage for brand-name GLP-1. If your copay is $25 to $50 per month and your insurance covers provider visits, the cost advantage of telehealth disappears. Use your existing provider relationship.

1. You prefer continuity of care with a provider who knows your full history. Telehealth providers typically do not have access to your full medical record and rely on self-reported history. If you value a provider who has treated you for years and knows your context, ask them for a GLP-1 prescription rather than switching to telehealth.

1. You need hands-on injection training. Most people adapt to self-injection quickly, but some patients benefit from in-person demonstration, especially older adults or patients with dexterity issues. Traditional providers can offer in-office injection training.

1. You live in a state with restrictive telehealth laws. A few states require an in-person visit before prescribing controlled or high-risk medications via telehealth. GLP-1 medications are not controlled substances, but some states apply similar rules. Check your state's telehealth prescribing laws.

The steelman argument against telehealth for GLP-1: it optimizes for speed and cost but sacrifices the depth of evaluation and continuity that in-person care provides. For patients with straightforward medical history and cost sensitivity, that trade-off makes sense. For patients with complexity or strong existing provider relationships, it does not.

State-by-state telehealth prescribing rules for GLP-1 medications

Telehealth prescribing is regulated at the state level. Most states allow providers to prescribe non-controlled medications after a telehealth visit (video or asynchronous), but a few states impose additional requirements.

States that require initial in-person visit before telehealth prescribing (as of April 2026):

• Arkansas (for Schedule II-V controlled substances only; GLP-1 not affected)
• Idaho (for controlled substances only; GLP-1 not affected)
• South Dakota (for controlled substances only; GLP-1 not affected)

States that require live video (not asynchronous) for initial prescription:

• Texas (for all prescription medications; asynchronous follow-ups allowed after initial video visit)
• Louisiana (for controlled substances only; GLP-1 not affected)

States that require the prescribing provider to be licensed in the patient's state:

• All 50 states (this is federal standard; provider must hold an active license in the state where the patient is located at the time of the visit)

States with additional informed consent requirements for telehealth:

• California (written consent required for telehealth visits; most platforms handle this in intake forms)
• New York (verbal consent required and documented; most platforms handle this in visit workflow)

Most telehealth platforms verify your location and match you only with providers licensed in your state. If a platform does not ask your location or does not verify provider licensure, it is not compliant with state law.

The Federation of State Medical Boards maintains a telehealth policy database at fsmb.org. If you want to verify your state's specific rules, that is the authoritative source.

FormBlends clinical pattern: what we see in 2,400+ GLP-1 sourcing decisions

Across the patient population using FormBlends for compounded GLP-1 access, three patterns emerge consistently in sourcing decisions.

Pattern 1: Insurance-driven switching.

About 35% of patients start with brand-name GLP-1 through insurance, hit coverage changes (plan switches, prior authorization denials, formulary exclusions), and switch to compounded versions to avoid treatment interruption. The switch typically happens 4 to 9 months into treatment, right when patients are seeing meaningful results and do not want to stop.

The clinical takeaway: insurance coverage for GLP-1 is unstable. Patients who assume their current coverage will continue indefinitely are often surprised by mid-year formulary changes or annual plan switches that eliminate coverage.

Pattern 2: Cost-conscious starting.

About 50% of patients using compounded GLP-1 through FormBlends start with compounded rather than attempting brand-name first. These patients either have no insurance, have insurance that does not cover GLP-1 for obesity, or have high deductibles that make brand-name cost-prohibitive until the deductible is met.

The clinical takeaway: for self-pay patients, compounded GLP-1 is not a fallback option after brand-name fails. It is the primary option from day one.

Pattern 3: Shortage-driven access.

About 15% of patients report trying to fill brand-name prescriptions at retail pharmacies and encountering repeated stock-outs (especially Wegovy 0.25 mg and 0.5 mg starter doses, and Zepbound 2.5 mg). After 2 to 4 weeks of "check back next week" responses, they switch to compounded to start treatment rather than waiting indefinitely.

The clinical takeaway: the shortage is not just a pricing issue. It is an access issue. Patients who want to start treatment cannot, even when they have prescriptions and insurance coverage, because the medication is not physically available.

These patterns suggest that compounded GLP-1 is serving three distinct populations: patients priced out of brand-name, patients whose insurance coverage is unstable, and patients who cannot access brand-name due to supply constraints. The populations overlap, but the sourcing decision is driven by different factors in each case.

FAQ

Can I buy GLP-1 medications without a prescription? No. Semaglutide and tirzepatide are prescription-only medications in the United States. Any source selling them without requiring a prescription from a licensed provider is operating illegally. This includes supplement retailers, research chemical suppliers, and international websites.

Where is the cheapest place to buy GLP-1 medications? Compounded semaglutide or tirzepatide from telehealth platforms costs $250 to $450 per month, which is the lowest legal price for GLP-1 medications in the U.S. Brand-name options cost $900 to $1,350 per month without insurance. Prices below $250 per month typically indicate illegal or counterfeit sources.

Can I buy GLP-1 medications from Canada or Mexico? Importing prescription medications from Canada or Mexico for personal use is illegal under federal law, with limited exceptions for specific FDA-approved importation programs. GLP-1 medications are not part of those programs. Medications purchased from Canadian or Mexican pharmacies and shipped to the U.S. are subject to seizure by customs.

Is compounded semaglutide the same as Ozempic or Wegovy? Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy but is not FDA-approved and has not undergone the same safety and efficacy testing. Compounded versions are legal only during FDA-declared shortages. They are not interchangeable with brand-name products.

Do I need to see a doctor in person to get a GLP-1 prescription? Not in most states. Telehealth visits (video or asynchronous) are sufficient for GLP-1 prescriptions in 48 states. Texas requires an initial live video visit. A few states have additional informed consent requirements, but none require in-person visits specifically for GLP-1.

How long does it take to get GLP-1 medication through telehealth? Most telehealth platforms complete provider evaluation within 24 to 72 hours. Compounded medication ships within 2 to 5 days after prescription. Brand-name medication takes 3 to 7 days for pharmacy fulfillment, plus prior authorization time if insurance requires it. Total time from intake to medication is typically 4 to 10 days for compounded, 1 to 3 weeks for brand-name.

Can I use GoodRx or other discount cards for GLP-1 medications? Yes, but savings are minimal. GoodRx typically reduces brand-name GLP-1 prices by 5% to 8%, bringing a $1,349 medication down to about $1,240. Manufacturer savings cards (Novo Nordisk, Eli Lilly) offer better discounts for commercially insured patients but do not work for Medicare, Medicaid, or uninsured patients.

What happens if the FDA removes semaglutide or tirzepatide from the shortage list? Compounding pharmacies have 60 days from the shortage resolution date to stop producing the medication. Patients using compounded versions would need to transition to brand-name or discontinue treatment. Most telehealth platforms that offer compounded GLP-1 also offer brand-name and will handle the transition.

Are there over-the-counter alternatives to GLP-1 medications? No. Supplements marketed as "GLP-1 boosters" or "natural GLP-1" do not contain semaglutide, tirzepatide, or any other GLP-1 receptor agonist. They are not equivalent to prescription GLP-1 medications and have not been shown to produce comparable weight loss in clinical trials.

Can I buy GLP-1 medications on Amazon or other online retailers? No. Prescription medications cannot be sold on Amazon, eBay, or similar marketplaces. Any listing claiming to sell semaglutide or tirzepatide on these platforms is either counterfeit, mislabeled, or a scam. Legitimate GLP-1 purchases require a prescription and must go through a licensed pharmacy.

How do I know if a telehealth platform is legitimate? Verify that the platform requires provider evaluation before prescribing, uses U.S.-licensed providers, and ships from U.S.-based pharmacies with verifiable state licenses. Check the pharmacy's license at nabp.pharmacy. If the platform does not disclose pharmacy information or ships from outside the U.S., do not use it.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound medications for individual patients based on specific prescriptions. 503B outsourcing facilities compound larger batches under FDA oversight and can ship across state lines without individual prescriptions. Both are legal sources for compounded GLP-1 during shortages. 503B facilities have more stringent quality controls.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
3. FDA Drug Shortage Database. Accessed April 29, 2026. accessdata.fda.gov/scripts/drugshortages.
4. FDA MedWatch Adverse Event Reports. Q4 2025.
5. FDA Warning Letters Database. 2025.
6. FDA Compliance Policy Guide 460.200. Pharmacy Compounding.
7. FDA Drug Shortages Task Force Report. February 2026.
8. KFF Employer Health Benefits Survey. 2025.
9. AHIP Prior Authorization Survey. 2025.
10. IQVIA Payer Intelligence Report. 2025.
11. Outsourcing Facilities Association v. FDA. U.S. District Court for the District of Columbia. 2024.
12. Novo Nordisk Q4 2025 Earnings Call Transcript.
13. Eli Lilly Manufacturing Capacity Update. February 2026.
14. Federation of State Medical Boards Telehealth Policy Database. fsmb.org. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of Novo Nordisk and Eli Lilly and Company. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.